Publications by authors named "Johannes Pipping"
Article Synopsis
- Cystic fibrosis (CF) is characterized by immune dysregulation and chronic inflammation, and this study focused on the effects of the CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) on associated inflammation in patients with CF.
- Researchers analyzed plasma samples from 51 patients before, three months, and six months after starting ETI therapy, measuring various pro-inflammatory chemokines.
- Results showed significant improvements in lung function and decreases in specific inflammatory markers, particularly those linked to neutrophilic inflammation, indicating ETI's anti-inflammatory effects.
Article Synopsis
- Cystic fibrosis (CF) lung disease features chronic infections and immune dysfunction, and CFTR modulators like elexacaftor/tezacaftor/ivacaftor have been shown to improve clinical outcomes in patients with CF, but their effect on inflammation is unclear.*
-
- In a study of 77 patients, 3 months of treatment with elexacaftor/tezacaftor/ivacaftor resulted in significant improvements in lung function (12.5% increase in FEV1) and a marked increase in regulatory T cells (Tregs) by 18.7%, especially in those clearing Pseudomonas aeruginosa.*
-
- Additionally, there was a
